Harvard Bioscience Reports Q3 Revenue Growth Amid Lowered FY2026 Outlook
Harvard Bioscience (HBIO) reported third-quarter GAAP earnings per share of -$0.06, with revenue reaching $22.2 million, representing a 7.8% increase year-over-year. Despite the top-line growth, the company's financial outlook for fiscal year 2026 has been adjusted downward. The company now expects FY2026 revenue growth to fall within the range of 3% to 5%. More significantly, Harvard Bioscience lowered its adjusted EBITDA growth guidance from a previous projection of 6%-10% to a much more conservative range of -1% to 4%. Adjusted gross margins are projected to be between 57% and 59%.
Tickers: $HBIO
Topics: earnings report financial results guidance downgrade revenue growth